Form 8-K · Current Report · Filed 2024-11-12
Roivant Reports Q2 Financial Results and Business Updates
Roivant Sciences Ltd. reported its Q2 financial results for 2024, showcasing a net loss of $236.8 million, a slight improvement from the previous quarter's $244.6 million loss. The company's cash position remained strong at approximately $5.4 billion. Roivant highlighted positive clinical data across several pipeline programs, including sustained efficacy in non-infectious uveitis and promising results in Graves' disease. The company also announced the close of Organon's acquisition of Dermavant, receiving $184M in cash and additional milestone payments contingent on FDA approval.
- Filer
- Roivant Sciences Ltd ROIV · NASDAQ
- Filed
- Accession
- 0001140361-24-046015
- CIK
- 0001635088
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$11.81
Next session
+1.2%
Since filing
+193.3%
Latest close
$34.64
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ROIV reporting the same item, with the next session's move:
Exhibits (1)
About Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.
Never miss another ROIV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.